its TRACTr drugs have been shown to offer the same anti-tumour activity as older T-cell engager drugs, but don’t cause the release of cytokines that can lead to a runaway immune response and ...

The first-in-human study is the first readout from the company’s pipeline of tumour-activated TCE (TRACTr) therapies, designed to overcome the limitations of the class in treating solid tumours.

Janux Therapeutics, Inc. ( ($JANX) ) has released its Q4 earnings. Here is a breakdown of the information Janux Therapeutics, Inc. presented to ...

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of ...

Tumor Activated T-cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) are two unique platforms that the company has created. Janux Therapeutics, Inc. (NASDAQ:JANX) develops safe ...

Zach’s expertise in T cell engagers has brought significant value to our organization and he has been essential in our efforts to optimize the clinical development of our PSMA-TRACTr and ...

(Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr ...

“2024 was an exceptional year for Janux as we displayed the potential power of our TRACTr platform in the clinic. We believe the data recently presented from JANX007 demonstrated substantial ...